Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia

Blood

Volumn 118, Issue 24, 2011, Pages 6310-6320

  Bluteau, Dominique ^a,b,c   Gilles, Laure ^a,b,c   Hilpert, Morgane ^a,b,c   Antony Debré, Iléana ^a,b,c   James, Chloe ^a,d   Debili, Najet ^a,b,c   Camara Clayette, Valerie ^a,b,c   Wagner Ballon, Orianne ^a,b,c   Cordette Lagarde, Veronique ^a,b,c   Robert, Thomas ^b,c   Ripoche, Hugues ^b,c,e   Gonin, Patrick ^c   Swierczek, Sabina ^f   Prchal, Josef ^f   Vainchenker, William ^a,b,c   Favier, Remi ^a,g   Raslova, Hana ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e CNRS   (France)

^f UNIVERSITY OF UTAH   (United States)

^g ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DOWN REGULATION; GENE; GENE EXPRESSION; GENE MUTATION; HEMATOPOIESIS; HUMAN; NR4A3 GENE; PEDIGREE; PRIORITY JOURNAL; STEM CELL;

EID: 83455210382     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-325555     Document Type: Article

References (36)

1. Niebuhr B, Fischer M, Täger M, Cammenga J, Stocking C. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Blood Cells Mol Dis. 2008;40(2):211-218. (Pubitemid 351221378)
2. Song WJ, Sullivan MG, Legare RD, et al. Haplo-insufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2): 166-175. (Pubitemid 29455388)
3. Arepally G, Rebbeck TR, Song W, Gilliland G, Maris JM, Poncz M. Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML). Blood. 1998;92(2):2600-2602.
4. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99(4):1364-1372. (Pubitemid 34547093)
5. Ganly P, Walker LC, Morris CM. Familial mutations of the transcription factor RUNX1 (AML1, CBFA2) predispose to acute myeloid leukemia. Leuk Lymphoma. 2004;45(1):1-10. (Pubitemid 38181387)
6. Kirito K, Sakoe K, Shinoda D, Takiyama Y, Kaushansky K, Komatsu N. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Haematologica. 2008;93(1):155-156. (Pubitemid 351156172)
7. Walker LC, Stevens J, Campbell H, et al. A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. Br J Haematol. 2002;117(4):878-881. (Pubitemid 34639250)
8. Shinawi M, Erez A, Shardy DL, et al. Syndromic thrombocytopenia and predisposition to acute myelogenous leukemia caused by constitutional microdeletions on chromosome 21q. Blood. 2008;112(4):1042-1047.
9. Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia-a review. Br J Haematol. 2008;140(2):123-132. (Pubitemid 350265048)
10. Owen CJ, Toze CL, Koochin A, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 2008;112(12):4639-4645.
11. Beri-Dexheimer M, Latger-Cannard V, Philippe C, et al. Clinical phenotype of germline RUNX1 haploinsufficiency: from point mutations to large genomic deletions. Eur J Hum Genet. 2008;16(8): 1014-1018.
12. Buijs A, Poddighe P, van Wijk R, et al. A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood. 2001;98(9):2856-2858.
13. Preudhomme C, Renneville A, Bourdon V, et al. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood. 2009;113(22):5583-5587.
14. Jongmans MC, Kuiper RP, Carmichael CL, et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. Leukemia. 2010;24(1): 242-246.
15. van der Crabben S, van Binsbergen E,Ausems M, Poot M, Bierings M, Buijs A. Constitutional RUNX1 deletion presenting as non-syndromic thrombocytopenia with myelodysplasia: 21q22 ITSN1 as a candidate gene in mental retardation. Leuk Res. 2010;34(1):e8-e12.
16. Churpek JE, Garcia JS, Madzo J, Jackson SA, Onel K, Godley LA. Identification and molecular characterization of a novel 3′ mutation in RUNX1 in a family with familial platelet disorder. Leuk Lymphoma. 2010;51(10):1931-1935.
17. Gilles L, Guieze R, Bluteau D, et al. P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood. 2008;111(8):4081-4091.
18. Dupont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hyper-sensitivityand terminal erythroid amplification inprimary cells from patients with polycythemiavera. Blood. 2007;110(3):1013-1021. (Pubitemid 47267441)
19. Croisille L, Auffray I, Katz A, Izac B, VainchenkerW,Coulombel L. Hydrocortisone differentially affectsthe ability of murine stromal cells and humanmarrow-derived adherent cells to promote thedifferentiation of CD34++/CD38- long-termculture-initiating cells. Blood. 1994;84(12):4116-4124.
20. Debili N, Masse JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Effects of the recombinanthematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitoryfactor on the megakaryocytic differentiationof CD34+ cells. Blood. 1993;82(1):84-95. (Pubitemid 23188750)
21. Baccini V, Roy L, Vitrat N, et al. Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes.Blood. 2001;98(12):3274-3282.
22. Hattori K. An improved method of peroxidase reactioncombined with Giemsa's stain for bloodcells. J Lab Clin Med. 1958;51(5):829-834.
23. Osato M. Point mutations in the RUNX1/AML1gene: another actor in RUNX leukemia. Oncogene.2004;23(24):4284-4296. (Pubitemid 38765137)
24. Mullican SE, Zhang S, Konopleva M, et al. Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. Nat Med. 2007;13(6):730-735. (Pubitemid 46889752)
25. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics. 2005;6: 79.
26. Sun W, Downing JR. Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors. Blood. 2004;104(12): 3565-3572. (Pubitemid 39564428)
27. Cammenga J, Niebuhr B, Horn S, et al. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation. Cancer Res. 2007; 67(2):537-545. (Pubitemid 46192190)
28. Watanabe-Okochi N, Kitaura J, Ono R, et al. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood. 2008;111(8):4297-4308.
29. Schindler JW, Van Buren D, Foudi A, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell. 2009;5(1):43-53.
30. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10(3):299-304. (Pubitemid 38667622)
31. Swierczek SI, Agarwal N, Nussenzveig RH, et al. Hematopoiesis is not clonal in healthy elderly women. Blood. 2008;112(8):3186-3193.
32. Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem. 2005;280(32): 29256-29262. (Pubitemid 41161379)
33. Li QX, Ke N, Sundaram R, Wong-Staal F. NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol Histopathol. 2006;21(5):533-540.
34. Ohkura N, Hijikuro M, Yamamoto A, Miki K. Molecular cloning of a novel thyroid/steroid receptor superfamily gene from cultured rat neuronal cells. Biochem Biophys Res Commun. 1994; 205(3):1959-1965.
35. Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood.117(9):2681-2690.
36. Kroeger H, Jelinek J, Estecio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008; 112(4):1366-1373.